PIM
PALI icon

Platinum Investment Management’s Palisade Bio PALI Stock Holding History

Platinum Investment Management’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Buy
1,231,414
+567,327
+85% +$1.03M 0.54% 60
2025
Q4 		$1.56M Buy
+664,087
New +$1.28M 0.36% 73

Other funds holding PALI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Platinum Investment Management's PALI Position: Q1 2026 in Review

Platinum Investment Management increased its Palisade Bio (PALI) stake by 85% in Q1 2026, buying an estimated $1.03M and bringing the position to 1,231,414 shares worth $2.15M. The position accounts for 0.54% of the portfolio, ranked #60.

Platinum Investment Management first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

  • Platinum Investment Management held 1,231,414 shares of Palisade Bio worth $2.15M as of Q1 2026.
  • Platinum Investment Management bought 567,327 Palisade Bio shares in Q1 2026, an estimated $1.03M.
  • Palisade Bio made up 0.54% of Platinum Investment Management's portfolio in Q1 2026, its #60 holding.
  • Platinum Investment Management first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Platinum Investment Management's 13F filing for Q1 2026, filed 14 May 2026.